Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

AARD

NASDAQ

Aardvark Therapeutics (AARD)

0.9279 USD −8.58% vs prior close Nov 20, 2026
Aardvark Therapeutics, Inc. price graph
64 sessions
8 0 24 Aug 20 Nov

The line runs 6.87 USD on 24 August through 0.9279 USD on 20 November, on a scale from 0 to 8. Days the market did not trade hold the previous close, flat.

Market cap
20.3M USD
Revenue, year to Dec 2025
0 USD
EPS, diluted, year to Dec 2025
−2.93 USD
Avg volume
25.9K

as of Nov 20, 2026

Have Aardvark Therapeutics (AARD) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Aardvark Therapeutics insiders reported 2 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 11 Dec 2025.

Form 4, 90 days to 22 Nov 2026, newest reported trade 11 Sep 2026

0buys
2sells
$395Knet sold
0other filings
Have Aardvark Therapeutics (AARD) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
11 Sep 2026Sun NelsonSee RemarksSell62,000321K USD
10 Sep 2026Sun NelsonSee RemarksSell14,75474K USD
Sold2 open-market sales76,754$395K

Which funds hold Aardvark Therapeutics (AARD)?

7 of the 45 institutional funds we track reported a Aardvark Therapeutics position for the quarter ended 30 Sep 2026 — a combined 7.8M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Aardvark Therapeutics (AARD)?
FundPositionSharesValueShares q/q
Citadel AdvisorsHeld (±25%)975,0285.1M USD−24.0%
Marshall WaceAdded132,204697K USD+593.0%
Two Sigma InvestmentsHeld (±25%)129,577683K USD+19.6%
AQR Capital ManagementTrimmed114,053601K USD−76.3%
Millennium ManagementHeld (±25%)62,454329K USD−10.7%
D. E. Shaw & Co.New position40,558214K USD
Point72 Asset ManagementAdded35,456187K USD+55.0%

What has been filed or recorded for Aardvark Therapeutics (AARD)?

The filings we hold for Aardvark Therapeutics, newest first: 8 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Aardvark Therapeutics (AARD)?
And
30 Oct 2026Fails to deliverShares failed to deliver176,079 shares254K USD notional · 0.804% of shares out
29 Oct 2026Fails to deliverShares failed to deliver302,948 shares457K USD notional · 1.384% of shares out
28 Oct 2026Fails to deliverShares failed to deliver507,252 shares659K USD notional · 2.317% of shares out
27 Oct 2026Fails to deliverShares failed to deliver501,028 shares541K USD notional · 2.289% of shares out
26 Oct 2026Fails to deliverShares failed to deliver306,616 shares426K USD notional · 1.401% of shares out
23 Oct 2026Fails to deliverShares failed to deliver17,353 shares69K USD notional · 0.079% of shares out
22 Oct 2026Fails to deliverShares failed to deliver94 shares415 USD notional · <0.001% of shares out
08 Oct 2026Fails to deliverShares failed to deliver198 shares982 USD notional · 0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.88 USD
30 Sep 2026FinancialsTotal assets64.8M USDat period end
30 Sep 2026FinancialsTotal equity57.6M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.66 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.99 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −2.93 USD
31 Dec 2025FinancialsRevenue0 USDfiscal year
31 Dec 2025FinancialsNet income−57.6M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−2.93 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.75 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.66 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.71 USD
31 Dec 2024Annual reportFY 2025 reportedEPS −5.15 USD

What do people ask about Aardvark Therapeutics (AARD)?

From live data
What did Aardvark Therapeutics shares close at?0.9279

Aardvark Therapeutics closed at 0.9279 USD on 20 Nov 2026, down 8.58% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Aardvark Therapeutics’ market cap?20.3M

Aardvark Therapeutics is worth 20.3M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.

What is Aardvark Therapeutics’ revenue?0

Aardvark Therapeutics reported revenue of 0 USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Aardvark Therapeutics insiders bought or sold shares recently?2 sales

In the 90 days to 22 Nov 2026, Aardvark Therapeutics insiders reported 2 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 11 Dec 2025. See Insiders

Which funds own Aardvark Therapeutics?7 of 45

7 of the 45 funds we track reported a Aardvark Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Marshall Wace and Two Sigma Investments. See Funds

When did Aardvark Therapeutics last report earnings?−0.88

Aardvark Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.88 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words